entertainment -WSS

entertainment

author：knowledge 2025-09-27 10:01:35 - browse：54642

Stacks of silver coins surrounded by a medicare health insurance card — insurance coverage from STAT — A federal rule that could make Medicare reimbursement for breakthrough devices easier is slated for early summer. Adobe

WASHINGTON — A federal rule aiming to make reimbursement for breakthrough devices easier is slated for early summer, a Centers for Medicare and Medicaid Services official said on Thursday.

The agency has faced intense pressure from device makers frustrated with the slow pace of Medicare reimbursement decisions. Medical technology lobby AdvaMed sent CMS a strongly-worded letter in March asking why it has taken so long to get the breakthrough device program moving.

Dora Hughes, director of the clinical standards center at CMS, told attendees at the Medical Device Manufacturers’ Association conference the agency wanted to take the time to meaningfully address feedback sent during the comment period, which closed in August. She also noted the organization’s goal of releasing the final rule with a slate of other policies, including a rule clarifying the agency’s thinking on what kind of evidence would be needed to convince the agency that a given device is both reasonable and necessary.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Senators: Long

WSS

How AI helped researchers track recovery from depression

CDC recommends RSV monoclonal antibody for infants

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

It costs an awful lot of money to give away a kidney

Lasker Awards 2023: Winners in biomedical research

Biotech lab space demand falls sharply

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Drug repurposing or repositioning? The language matters

It's been 20 years since Dolly the sheep. Where's my clone?

In Memoriam: Notable people who died in 2023

Thermo Fisher plant for manufacturing gene therapies to expand

Bright Health sells Medicare Advantage business to Molina

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Sports medicine is finally prioritizing gender equality

When waiting feels immoral: Empathy in the emergency department

Supreme Court strikes down use of affirmative action

2 officers injured in shooting in Orlando, police say

explore

Late stage cancers on the rise after pandemic delayed screenings

Changes to biosimilar regulatory framework must prioritize patients

2 officers injured in shooting in Orlando, police say

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

The a glaring gap in research on serious mental illness and primary care

Chris Christie meets with Zelenskyy during Ukraine trip

focus

hotspot

leisure time

hotspot